NCT02632747View on ClinicalTrials.gov

Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

May 10, 2016

Primary Completion Date

December 19, 2017

Study Completion Date

July 2, 2019

Conditions
Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Obesity
Interventions
DRUG

Empagliflozin

Empagliflozin will be taken once daily

DRUG

Placebo (matching empagliflozin)

Placebo will be taken once daily

DRUG

ramipril

Ramipril will be taken once or twice daily

Trial Locations (1)

M5G 2N2

Toronto General Hospital, Toronto

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Boehringer Ingelheim

INDUSTRY

NCT02632747 - Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study | Biotech Hunter | Biotech Hunter